Out of the abyss: 3Q23 market preview

With a robust rebound in the second quarter, the biotech sector is poised for a more constructive back half of 2023 as it charts a path to recovery.

Positive shifts in the capital markets are becoming evident, with buyside investors reporting an increase in pre-IPO meetings to test the waters and a perceived thawing of the market. This, coupled with a rise in M&A activity and follow-on offerings, indicates a more favorable environment for biotech companies...